7 Best Peptides for Liver Health

What to Know Before Choosing a Peptide for Liver Health

The peptide landscape for liver health is wider and more varied than most people realize. At one end sits a small group of FDA-approved compounds with rigorous human trial data showing meaningful effects on fatty liver disease, liver inflammation, and fibrosis. At the other end sits a set of research-stage and community-use compounds with years of preclinical work behind them and no published human trial data for this application. Most people searching this topic will encounter both kinds of compound in the same conversation, and understanding where each one stands matters before making any decision.

Every compound in this guide earned its place because people use it for liver health, or are actively discussing using it for that purpose. The list is not filtered by FDA approval status, clinical trial depth, or regulatory classification. FDA-approved, telemedicine-prescribed, and research-only compounds are all represented. Where the evidence is strong and comes from human trials, that is stated plainly. Where it comes from animal models only, or from community protocols with no controlled data behind it, that is stated just as plainly. Evidence strength shapes how each compound is described, not whether it appears.

The compounds are numbered, but the numbers reflect an ordering, not a ranking. The order tracks how prominently each compound appears in published research and real-world use for liver health, which means the first entry has the deepest clinical footprint for this goal, not that it is the right choice for any particular person. Individual circumstances, health history, and everything else someone is doing all matter enormously in this space. The ordering is a map of the field. What you do with that map is the conversation to have with a qualified healthcare provider and, when you are ready to build a plan, with the MyPeptidePal app.

1. Semaglutide: The Only Peptide FDA-Approved for Liver Disease

Semaglutide is a GLP-1 receptor agonist, a compound that works by mimicking glucagon-like peptide-1, a hormone the gut releases after eating that signals the pancreas to release insulin and tells the brain the body is full. It was first developed for type 2 diabetes and obesity, but its effects on the liver proved substantial enough to earn it a specific FDA indication. In August 2025, semaglutide became the first peptide approved specifically for metabolic dysfunction-associated steatohepatitis, the more severe inflammatory form of fatty liver disease, in patients who also have liver fibrosis.

The clinical evidence behind that approval is genuinely strong. In a Phase 2 randomized controlled trial, semaglutide produced NASH resolution in 59% of participants compared to 17% in the placebo group. The compound acts on the liver through several interlocking mechanisms: it activates AMPK, a cellular energy-sensing switch that tells the liver to stop manufacturing fat; it suppresses hepatic lipogenesis directly; it reduces the triglyceride accumulation that characterizes fatty liver disease; and it improves insulin sensitivity, which matters because insulin resistance is one of the primary drivers of fatty liver progression. Real-world accounts from people using semaglutide through telemedicine platforms consistently mention normalized liver enzyme levels as a secondary benefit, with some users reporting ALT and AST values in the optimal range after a year or more of use.

Semaglutide is available by prescription through licensed telemedicine and clinical channels for its approved indications. Off-label use for liver-specific outcomes requires working with a specialist who can supervise the indication properly. The compound has a well-characterized safety profile from years of large-scale human use, and gastrointestinal side effects are the most commonly reported challenge.

2. Tirzepatide: The Dual Agonist with the Largest Liver Fat Reductions

Tirzepatide adds a second mechanism to the GLP-1 pathway by also activating the GIP receptor, a receptor that responds to glucose-dependent insulinotropic polypeptide, another gut-derived hormone involved in metabolic signaling. That dual activation produces stronger metabolic effects than GLP-1 agonism alone, and for the liver, the numbers are striking. The SYNERGY-NASH trial, with results published in the New England Journal of Medicine, showed significant fibrosis improvement alongside absolute liver fat reductions of up to 8%, outcomes that represent meaningful clinical change in a disease that has historically been difficult to treat.

Tirzepatide does not yet carry a liver-specific approval the way semaglutide does, but clinical trial evidence for liver outcomes is accumulating. In community discussions, tirzepatide is the compound most frequently cited by people reporting measurable liver marker improvement. Users describe liver enzymes moving from elevated to solidly normal within a few months of consistent use. A consistent pattern also appears across many independent reports: the reduction in alcohol cravings that tirzepatide produces contributes to liver recovery in people whose fatty liver had an alcohol component, alongside the direct metabolic effects. The compound is available by prescription through licensed telemedicine and clinical channels for its approved indications in obesity and type 2 diabetes.

3. Liraglutide: The Earlier GLP-1 with Confirmed NASH Resolution

Liraglutide is an earlier GLP-1 receptor agonist with a shorter half-life than semaglutide and a longer track record in clinical use overall. Its liver evidence comes from the LEAN trial, a Phase 2 randomized controlled study that confirmed NASH resolution and produced a fibrosis signal in participants, making it one of the foundational studies demonstrating that the GLP-1 mechanism has real hepatic effects rather than purely metabolic ones. The LEAN trial preceded the larger semaglutide liver work and helped establish the biological rationale for the compounds that followed.

Liraglutide is not specifically approved for liver disease, but it carries the same prescription availability as semaglutide and tirzepatide through its obesity and type 2 diabetes indications. In current community discussions about liver health it appears less frequently than the newer GLP-1 compounds, largely because the options available through telemedicine have expanded and semaglutide and tirzepatide tend to be preferred when people have access to the full range. Its evidence base for liver outcomes is solid, grounded in human trial data, and it belongs in any complete account of the GLP-1 compounds studied for this goal.

4. BPC-157: The Research Peptide with the Deepest Preclinical Liver Record

BPC-157, or Body Protection Compound-157, is a synthetic peptide derived from a protein found in gastric juice. It has no FDA approval for any indication, and the FDA has raised concerns about compounded versions of the compound, specifically around immunogenicity risks. Its relevance to liver health rests on more than three decades of animal research, making it by a wide margin the research-stage compound with the deepest preclinical liver data set of any option in community use.

In animal models, BPC-157 has shown hepatoprotective effects across several distinct types of liver injury: chemically induced damage, radiation injury, and ischemia-reperfusion injury, which is the harm that occurs when blood flow is restored to liver tissue after a period of oxygen deprivation. The primary mechanism identified in this research involves upregulation of KLF4, a transcription factor that plays roles in both hepatocyte protection and the suppression of fibrosis-driving processes. The compound also reduces key inflammatory signaling molecules including TNF-alpha, IL-6, and IL-1-beta in these animal models, and research has connected it to gut-liver axis support through its effects on intestinal tissue.

No human clinical trial data has been published for BPC-157 in liver outcomes as of 2026. What exists in human-use accounts is anecdotal: claims that the compound supports liver recovery when taken orally, with no verified blood-work data from controlled conditions. Community discussion exists, but the pattern of use is more cautious than with BPC-157 protocols aimed at injury or gut health, where the compound is far more widely referenced. The FDA's concerns about compounded versions are worth noting for anyone considering it.

5. TB-500: For Anti-Fibrotic Support in Research Settings

TB-500 is the research-community name for synthetic thymosin beta-4, a peptide that occurs naturally in the body and plays roles in cell migration, wound healing, and tissue repair. It is not FDA-approved for liver disease, and like BPC-157 it is used as a research chemical outside licensed medical supervision. Its specific relevance to liver health is anti-fibrotic: animal research suggests it can interrupt the fibrosis cascade, the process by which liver injury progressively becomes scar tissue and, if unchecked, eventually cirrhosis.

The mechanism behind these observations centers on TGF-beta-1, the primary signaling molecule that instructs liver stellate cells to produce the collagen that forms scar tissue. Thymosin beta-4 appears to downregulate this pathway in animal models. It has also been shown in preclinical work to reverse the expression of caspase-3 and caspase-9, two proteins that drive programmed cell death in damaged hepatocytes, the specialized liver cells that carry out the liver's functional work. Addressing both the fibrosis-signaling pathway and the hepatocyte cell-death pathway gives the anti-fibrotic case for TB-500 a mechanistic specificity that goes beyond a generic cytoprotective claim.

The evidence base is animal-model research with no published human clinical trial data for liver outcomes as of 2026. Translation to human liver disease has not been directly established. In community protocols focused on liver recovery, TB-500 appears less often than BPC-157, typically raised in discussions about fibrosis concerns rather than general fatty liver conditions.

6. GHK-Cu: The Antioxidant Copper Peptide Originally Identified as Hepatotrophic

GHK-Cu is a copper-binding tripeptide, glycine-histidine-lysine complexed with a copper ion, that was originally identified in human plasma as a compound with liver-growth-promoting properties, a characteristic scientists describe as hepatotrophic. It is produced naturally by the body, and most people encounter it in consumer contexts as a topical skincare ingredient, where it is available without a prescription. For liver health purposes, interest centers on its antioxidant activity and its suppression of TGF-beta, the same fibrosis-driving signaling molecule targeted by TB-500.

In cell culture and animal studies, GHK-Cu reduces reactive oxygen species, the chemically aggressive molecules that damage liver cells under conditions of oxidative stress, by roughly 50% at concentrations studied in the laboratory. That level of reduction outperforms glutathione, one of the liver's primary endogenous antioxidants, specifically in neutralizing hydroxyl radicals, the most destructive of the reactive oxygen species. The compound also upregulates antioxidant enzyme expression and inhibits lipid peroxidation, the chain reaction through which oxidized fats damage cell membranes in fatty liver conditions. Its TGF-beta suppression adds an anti-fibrotic dimension alongside the antioxidant activity.

The evidence is preclinical, drawn from in vitro cell studies and animal models with no published human clinical trial data for liver outcomes as of 2026. GHK-Cu appears in community discussions of liver health less often than BPC-157 or the GLP-1 compounds, most often raised by people interested in its antioxidant properties alongside other compounds rather than as a primary liver health protocol.

7. MOTS-c: The Mitochondria-Derived Peptide for Metabolic Liver Disease

MOTS-c is a mitochondria-derived peptide, meaning it is encoded not in the nuclear genome but in the much smaller mitochondrial genome, the genetic material housed inside the cell's energy-producing organelles. It belongs to a class called mitochondria-derived peptides, which also includes humanin and the small humanin-like peptides. Among this group, MOTS-c has the most detailed and mechanistically specific preclinical work in liver disease models.

The mechanisms are layered. MOTS-c inhibits the TGF-beta-1 to Smad2/3/4 signaling pathway, a specific molecular route through which TGF-beta-1 instructs liver stellate cells to produce fibrotic scar tissue. It also directly binds the BH3 domain of BCL2, an anti-apoptotic protein, stabilizing it and blocking the activation of BAX, a protein that would otherwise trigger programmed cell death in hepatocytes. On the metabolic side, it activates AMPK through AICAR accumulation, a process that mimics an energy deficit inside the cell and suppresses the lipogenesis driving fat accumulation in metabolic liver disease. That combination of anti-fibrotic, anti-apoptotic, and metabolic activity in a single compound makes MOTS-c one of the more mechanistically detailed research-stage options in this space.

The evidence is preclinical, derived from metabolic liver disease animal models with no published human clinical trial data for liver outcomes as of 2026. MOTS-c is not available as a consumer supplement and is not prescribed through telehealth channels for liver health. It sits firmly in the research and early investigational category, representing active scientific interest rather than a compound people are currently running in organized community protocols at any scale.

How These Peptides Compare

Frequently Asked Questions

Which peptides in this guide have human clinical evidence for liver health?

Three compounds have been studied in human randomized controlled trials for liver outcomes: semaglutide, tirzepatide, and liraglutide, all GLP-1 receptor agonists. Semaglutide is the only one with an FDA approval specifically for a liver disease indication, granted in August 2025 for metabolic dysfunction-associated steatohepatitis with fibrosis. The remaining compounds in this guide, including BPC-157, TB-500, GHK-Cu, and MOTS-c, have no published human clinical trial data for liver outcomes as of 2026.

Are GLP-1 receptor agonists safe to use for liver health?

GLP-1 receptor agonists have well-characterized safety profiles built from large-scale clinical trials and years of real-world use in diabetes and obesity management. They do not typically cause liver toxicity and are generally considered safe for the liver at studied doses. The most commonly reported side effects are gastrointestinal, tending to be most prominent when doses are first adjusted, and anyone considering these compounds should work with a licensed healthcare provider who can assess individual eligibility and supervise the protocol appropriately.

What is the difference between a prescription peptide and a research peptide for liver health?

Prescription peptides like semaglutide, tirzepatide, and liraglutide have been through rigorous human clinical trials, carry established safety profiles, and are dispensed through licensed medical channels with physician oversight. Research peptides like BPC-157, TB-500, and GHK-Cu have not been approved for any medical indication, have no human clinical trial data for liver outcomes, and are typically sold as research chemicals through channels that carry no quality guarantee or medical supervision. The distinction matters because prescription peptides bring a level of quality control and oversight that research peptides accessed outside medical channels do not.

Can peptides replace diet, alcohol reduction, and weight loss for liver recovery?

No peptide studied for liver health is designed to replace the foundational interventions that drive liver recovery, including reducing or eliminating alcohol, improving diet quality, and managing conditions like insulin resistance and obesity. In the human trial data for GLP-1 agonists, liver benefits appear to come through a combination of direct hepatic effects and the metabolic improvements that accompany weight loss. Community reports consistently show people pairing peptide use with dietary changes, and many attribute a significant portion of their liver marker improvement to stopping or reducing alcohol alongside the metabolic effects of the compound.

How long does it typically take to see liver marker improvement on GLP-1 peptides?

Community reports and clinical trial data both suggest measurable changes in liver enzymes like ALT and AST can appear within three to six months of consistent use, with the SYNERGY-NASH trial showing meaningful fibrosis changes over longer follow-up periods. The timeline varies depending on starting condition, degree of metabolic improvement, and whether complementary changes like alcohol reduction are happening alongside treatment. Clinical trial follow-up periods for liver-specific outcomes typically run six months to a year or longer, reflecting how liver tissue responds gradually to sustained metabolic improvement rather than quickly to a short treatment course.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for liver health in one place.